Wednesday, July 8, 2026

pharma · Retinitis Pigmentosa · Dry Eye Disease · KPRX

KIORA PHARMACEUTICALS

KIORA PHARMACEUTICALS clinical programs — 5 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Encinitas, USA HQ
2013 Founded
18 Employees
Public company Type
KPRX · NYSE Ticker
Company details
Status
Public
HQ
Encinitas, USA
Founded
2013
Employees
18
Programs
5
Drugs
4
Patents
4
Intelligence · Clinical Programs

KIORA PHARMACEUTICALS projects

5 ClinicalTrials.gov programs sponsored by KIORA PHARMACEUTICALS.

KIORA PHARMACEUTICALS has 5 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. 100 μg KIO-301

    KIORA PHARMACEUTICALS INC

    Retinitis Pigmentosa

    phase 2 small molecule active

    1 trial
  2. KIO-101

    KIORA PHARMACEUTICALS INC

    Dry Eye Disease

    phase 2 small molecule terminated

    1 trial
  3. KIO-104

    KIORA PHARMACEUTICALS INC

    Macular Edema

    phase 2 small molecule active

    1 trial
  4. KIO-301

    KIORA PHARMACEUTICALS INC

    Retinitis Pigmentosa

    phase 2 small molecule completed

    1 trial
  5. OBG PED-001

    KIORA PHARMACEUTICALS INC

    Persistent Corneal Epithelial Defect

    phase 2 small molecule completed

    1 trial

Frequently asked questions

How many clinical projects does KIORA PHARMACEUTICALS have?

5 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.